Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial

Registros relacionados

• Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
  por: Mihaylova, B, et al.
  Publicado em: (2005)
• Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
  por: Mihaylova, B, et al.
  Publicado em: (2006)
• N-terminal pro-B-type natriuretic peptide and vascular disease among 20,536 patients in the MRC/BHF heart protection study
  por: Emberson, J, et al.
  Publicado em: (2005)
• Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.
  por: Armitage, J, et al.
  Publicado em: (2009)
• N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study
  por: Emberson, J, et al.
  Publicado em: (2005)